<DOC>
	<DOCNO>NCT02371070</DOCNO>
	<brief_summary>The investigator study aims test correlation Hemochron Signature point-of-care testing ( POCT ) device ( ITC , USA ) low plasma level three currently approve direct oral anticoagulant ( DOAC ; rivaroxaban , apixaban dabigatran ) determine diagnostic accuracy POCT rule detect relevant level DOAC real-life stroke patient .</brief_summary>
	<brief_title>Point-of-Care Testing Coagulation Patients Treated With Direct Oral Anticoagulants 2</brief_title>
	<detailed_description />
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Stroke patient , newly start oral anticoagulation rivaroxaban , apixaban dabigatran secondary prevention thromboembolic event Age ≥ 18 year Vitamin K antagonists direct oral anticoagulant ≤ 14 day prior study participation Lowmolecular weight heparin ≤ 24 hour Unfractionated heparin ≤ 12 hour Abnormal coagulation value baseline ( Quick &lt; 70 % activate thromboplastin time ( aPTT ) &gt; 40sec . ) History coagulopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>